Menu Search
Equities

Trinity Biotech PLC

TRB:DEU

Trinity Biotech PLC

Actions
  • Price (EUR)2.07
  • Today's Change0.00 / 0.00%
  • Shares traded660.20
  • 1 Year change-49.82%
  • Beta--
Data delayed at least 15 minutes, as of Feb 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.

  • Revenue in USD (TTM)56.83m
  • Net income in USD-36.87m
  • Incorporated1992
  • Employees380.00
  • Location
    Trinity Biotech PLCIda Business ParkBray, Co Wicklow, IrelandBRAY 18IrelandIRL
  • Phone+353 12769800
  • Fax+353 12769888
  • Websitehttps://www.trinitybiotech.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		TRIB:NSQ since
announced		Transaction
value
Waveform Technologies Inc-Continuous Glucose Monitoring AssetsAnnounced31 Jan 202431 Jan 2024Announced-27.19%21.50m
Data delayed at least 15 minutes, as of May 17 2024 20:59 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.